After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program Read More »
Experts say two new guidances — issued without the usual public comment period — leave questions about how patients will navigate a growing pool of wearables.
FDA guidance eases wearables oversight. But experts have questions about what’s next. Read More »
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo Read More »
The proposal would eliminate the financial motivation insurers have to mine their members’ charts for additional diagnoses. Regulators also proposed a flat rate update for 2027, prompting anger from insurers.
CMS proposes excluding chart reviews from MA risk scoring in 2027 payment rule Read More »
Una nueva técnica permite pronosticar erupciones volcánicas con aproximadamente 48 horas de antelación. La técnica ha sido desarrollada por el Instituto Geológico y Minero de España (IGME, dependiente del Consejo Superior de Investigaciones Cient&ia …
Nuevo método para predecir erupciones volcánicas con dos días de antelación Read More »
Un nuevo estudio revela un cambio sin precedentes en vertebrados: la temporada reproductiva de los pingüinos antárticos ha avanzado trece días en solo una década en respuesta al cambio climático global. Estos cambios amenazan con alterar el acceso de los pingüin …
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud Read More »
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
Baseline Debuts to Challenge GLP-1 Giant Lilly in Alcohol Use Disorder Read More »
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
Boehringer Commits Up to $1.26B in IBD Pact With China’s Simcere Read More »
A lo largo de los años, las sondas espaciales que han visitado Júpiter y Saturno han observado patrones climáticos desconcertantes en los polos de dichos mundos. Estos dos gigantescos planetas gaseosos albergan tipos muy diferentes de vórtices polares, que son enormes rem …
